Mitsubishi Tanabe Of Japan, Vertex Of U.S. Change Hepatitis C Pact
This article was originally published in PharmAsia News
Executive Summary
Japan's Mitsubishi Tanabe Pharma and U.S.-based Vertex Pharmaceuticals have revised their licensing agreement for the MP-424 (peginterferon) drug to treat hepatitis C. The drug is still in Phase III Japanese trials, but the companies decided a change was needed to help get the drug through those trials. Under the new arrangement, Mitsubishi Tanabe is to pay Vertex $105 million for a license to use the trial data to develop the drug for use in combination with interferon to treat hepatitis C. The new agreement eliminates royalties linked to sales. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.